RRAGC Antibody

What is RRAGC and why is it important in cellular signaling pathways?

RRAGC is a guanine nucleotide-binding protein that plays a crucial role in the cellular response to amino acid availability through regulation of the mTORC1 signaling cascade. It forms heterodimeric complexes with RagA/RRAGA or RagB/RRAGB and cycles between inactive GTP-bound and active GDP-bound forms. In its active GDP-bound form, RRAGC promotes the recruitment of mTORC1 to lysosomes and its subsequent activation by the GTPase RHEB .

Unlike most small GTPases which are active in their GTP-bound state, RRAGC is in its active form when GDP-bound. Specifically, when GDP-bound RRAGC forms a complex with GTP-bound RagA/RRAGA (or RagB/RRAGB), it is in its active form. Conversely, when GTP-bound RRAGC heterodimerizes with GDP-bound RagA/RRAGA (or RagB/RRAGB), it is in an inactive form .

How should I select the appropriate RRAGC antibody for my specific research application?

When selecting an RRAGC antibody, consider these methodological factors:

• Application compatibility: Determine whether the antibody has been validated for your specific application (WB, IHC, IP).

• Epitope location: For studying specific domains or post-translational modifications, select antibodies targeting relevant regions:

  • N-terminal region (aa 1-250): Suitable for studying GTP/GDP binding domains

  • C-terminal region (aa 300 to C-terminus): Better for studying protein interactions

• Species reactivity: Verify compatibility with your experimental model (human, mouse, etc.)

• Validation data: Review existing validation data, including published literature citing the antibody

Remember to validate the antibody in your specific experimental system by including appropriate controls .

How can I successfully use RRAGC antibodies for immunoprecipitation studies?

For effective immunoprecipitation (IP) of RRAGC, implement this methodological approach:

• Antibody selection: Use an antibody validated for IP applications, such as ab226199, which has been specifically validated for immunoprecipitation of RRAGC .

• Cell lysis optimization:

  • Use a gentle lysis buffer (e.g., 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate)

  • Include protease and phosphatase inhibitors to preserve protein interactions

  • Perform lysis on ice to minimize protein degradation

• IP protocol guidelines:

  • Antibody amount: 6 μg per reaction has been shown to successfully immunoprecipitate RRAGC from HEK-293T cell lysates

  • Pre-clear lysates with protein A/G beads to reduce non-specific binding

  • Incubate lysates with RRAGC antibody overnight at 4°C

  • Capture antibody-protein complexes with protein A/G beads (2-4 hours)

  • Wash extensively (4-5 times) to remove non-specific interactions

• Elution and detection strategies:

  • For co-IP studies detecting RRAGC interactions with mTORC1 components (e.g., Raptor), elute with SDS sample buffer

  • For analyzing RRAGC binding partners, consider milder elution conditions with peptide competition

• Co-IP validation:

  • When studying RRAGC interactions with binding partners like Raptor, use reciprocal IP (IP with anti-Raptor antibody, blot for RRAGC)

  • Include IgG control to identify non-specific binding

Example from literature: Successful IP of RRAGC from HEK-293T cells was achieved using 6 μg of ab226199 antibody per reaction with approximately 20% of the IP loaded for subsequent Western blot detection .

How do mutations in RRAGC affect mTORC1 signaling in follicular lymphoma?

RRAGC mutations in follicular lymphoma (FL) have significant functional consequences on mTORC1 signaling:

These findings suggest that RRAGC mutations represent a driver event in FL pathogenesis and identify RRAGC as a potential therapeutic target or biomarker for patient stratification .

What experimental models are available for studying RRAGC mutations in cancer?

Several experimental systems have been developed to study RRAGC mutations in cancer, particularly in follicular lymphoma:

• Genetically engineered mouse models:

  • RagC mutant mice (RagC S74C/+ and RagC T89N/+) expressing heterozygous RRAGC mutations

  • VavP-Bcl2 transgenic mice (VavP-Bcl2 tg; RagC mut) representing follicular lymphoma models with RRAGC mutations

  • Controls include RagA GTP/+ heterozygous mice for comparative analysis

• Cell line models:

  • Stably transfected HEK293T cells expressing HA-tagged wild-type or mutant RRAGC proteins

  • Lymphoma cell lines (OCI-LY1, OCI-LY7, SUDHL4) lentivirally transduced with wild-type or mutant RRAGC

  • Enrichment systems using GFP co-expression and FACS sorting for pure populations

• Yeast models:

  • Saccharomyces cerevisiae systems for studying RRAGC function in a simpler eukaryotic context

  • Useful for examining conserved pathways between yeast and mammals

• Experimental readouts:

  • Western blotting for mTORC1 signaling (pS6K, pS6, p4EBP1)

  • Immunoprecipitation for protein-protein interactions

  • RNA-seq for transcriptional profiling

  • GTP/GDP binding assays for nucleotide preference analysis

These models collectively provide complementary approaches for studying RRAGC biology in normal and malignant contexts .

How can I analyze RRAGC phosphorylation and its impact on mTORC1 regulation?

RRAGC phosphorylation represents an important regulatory mechanism for mTORC1 activity. Here's a methodological approach to study this process:

• Identification of phosphorylation sites:

  • Three conserved growth factor-responsive phosphorylation sites have been identified on RagC: S2, S21, and T394

  • mTORC1 itself has been identified as the upstream kinase for RagC on S21, revealing an autoregulatory mechanism

• Phosphorylation analysis methods:

  • Phospho-specific antibodies: When available, use antibodies specifically recognizing phosphorylated forms of RagC

  • Phospho-mimetic/null mutations: Create S2A/S21A/T394A (phospho-null) and S2E/S21E/T394E (phospho-mimetic) mutants through site-directed mutagenesis

  • Mass spectrometry: For unbiased identification of novel phosphorylation sites

  • In vitro kinase assays: Purify FLAG-RagC proteins and incubate with active mTOR fragments or other kinases

• Functional analysis of phosphorylation:

  • Autophagy assays: RagC phosphorylation suppresses starvation-induced autophagy

  • Cell growth assays: In Drosophila models, RagC phosphorylation plays an essential role in cell growth regulation

  • Nutrient response: Compare wild-type vs. phospho-mutant RagC in amino acid starvation/stimulation experiments

• Structural considerations:

  • S21 is located in a region that affects GTP/GDP binding and interactions with regulatory proteins

  • Phosphorylation likely alters conformational states of the protein, affecting its activity

These approaches provide comprehensive tools for analyzing how RagC phosphorylation contributes to mTORC1 regulation and cellular responses to nutritional status .

What computational methods can be used to model RRAGC structure and predict mutation effects?

Advanced computational methods can provide valuable insights into RRAGC structure and mutation effects:

• Structural modeling approaches:

  • Homology modeling: Using tools like PIGS server or AbPredict algorithm to generate 3D models based on known structures of related proteins

  • Automated docking: Simulating interactions between RRAGC and its binding partners (nucleotides, protein interactors)

• Mutation effect prediction pipeline:

  • Initial modeling of wild-type and mutant structures

  • Energy minimization to relax structures

  • Molecular dynamics simulations to capture conformational effects

  • Binding energy calculations to estimate effects on interaction partners

  • Comparison of nucleotide binding preferences between wild-type and mutant proteins

• Specific analysis techniques for RRAGC mutations:

  • Nucleotide binding pocket analysis: For mutations affecting GTP/GDP binding (e.g., S74C, T89N)

  • Protein-protein interface mapping: For mutations potentially affecting interactions with RagA/B or mTORC1 components

  • Electrostatic surface calculations: To predict changes in binding properties

  • Conservation analysis: To assess evolutionary importance of mutated residues

• Software tools commonly used:

  • Structure modeling: PIGS server, MOE (Molecular Operating Environment), AbPredict

  • MD simulations: AMBER, GROMACS

  • Visualization/analysis: PyMOL, VMD, Chimera

  • Binding energy calculations: MM-GBSA, FEP

• Validation of computational predictions:

  • Compare with experimental data such as STD-NMR results

  • Use experimental binding constants (Kd values) to validate computational predictions

  • Correlate structural models with functional assays (e.g., mTORC1 activation levels)

These computational approaches can provide mechanistic insights into how specific RRAGC mutations found in follicular lymphoma affect protein function, potentially guiding experimental design and therapeutic strategies .

What are common challenges when using RRAGC antibodies and how can I overcome them?

Researchers frequently encounter several challenges when working with RRAGC antibodies. Here's a methodological approach to identifying and resolving these issues:

• Multiple bands in Western blotting:

  Common causes:

  • Post-translational modifications (phosphorylation at S2, S21, T394)

  • Proteolytic degradation

  • Non-specific binding

  Solutions:

  • Include phosphatase inhibitors in lysis buffer to preserve phosphorylation states

  • Add protease inhibitor cocktail freshly to prevent degradation

  • Optimize antibody dilution (start with 1:1000 and adjust)

  • Try longer blocking times (2 hours) with 5% BSA instead of milk

  • Perform more stringent washes (5 x 5 minutes with 0.1% Tween-20)

  • For research requiring isoform specificity, use antibodies targeting unique epitopes

• Poor signal in immunohistochemistry/immunofluorescence:

  Common causes:

  • Insufficient antigen retrieval

  • Epitope masking

  • Low expression levels

  Solutions:

  • Optimize antigen retrieval methods (citrate buffer, pH 6.0 at 95°C for 20 minutes)

  • Test different fixation protocols (4% PFA for 15 minutes works well for most applications)

  • Increase antibody concentration for tissues (1:100-1:250 range)

  • Extend primary antibody incubation (overnight at 4°C)

  • Use amplification systems (e.g., biotin-streptavidin) for low abundance targets

• Failed immunoprecipitation:

  Common causes:

  • Harsh lysis conditions disrupting protein complexes

  • Insufficient antibody amount

  • Epitope masking in protein complexes

  Solutions:

  • Use gentle lysis buffers (e.g., 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% NP-40)

  • Increase antibody amount (6 μg has been validated for IP of RRAGC)

  • Try different antibodies targeting different epitopes

  • Crosslink antibody to beads to prevent antibody contamination in eluate

  • Extend incubation time (overnight at 4°C)

• Antibody storage and handling issues:

  Best practices:

  • Store according to manufacturer recommendations (typically -20°C)

  • Avoid repeated freeze-thaw cycles by making small aliquots

  • For antibodies like ab226199, use storage buffers with preservatives (e.g., 0.09% sodium azide)

  • Check expiration dates (typical guarantee is 12 months)

• Variable results between experiments:

  Standardization approach:

  • Use consistent positive controls (HEK293T cells express detectable RRAGC)

  • Maintain consistent sample preparation methods

  • Prepare master mixes for antibody dilutions

  • Document all experimental conditions thoroughly

  • Consider lot-to-lot variation when reordering antibodies

By systematically addressing these common challenges, researchers can optimize their experimental protocols for consistent and reliable results with RRAGC antibodies .

How can I design experiments to study RRAGC-dependent mTORC1 activation in response to amino acids?

Designing robust experiments to study RRAGC-dependent mTORC1 activation requires careful consideration of amino acid manipulation and signaling readouts:

• Experimental models for RRAGC function assessment:

  Cell-based systems:

  • Compare wild-type cells with RRAGC knockout/knockdown cells

  • Use cells expressing RRAGC mutations found in follicular lymphoma (S74C, T89N)

  • For B-cell specific studies, use primary B lymphocytes from RagC mutant mice

  Controls to include:

  • mTOR inhibitor treatment (rapamycin, Torin) as negative controls

  • Cells expressing constitutively active Rheb as positive controls

  • RagA mutant cells for comparison (mutations in RagA don't show the same signaling perturbations)

• Signaling readouts and methodologies:

  Western blotting targets:

  • Direct mTORC1 substrates: p-S6K (T389), p-4EBP1 (T37/46)

  • Downstream effectors: p-S6 (S235/236)

  Intracellular immunostaining:

  • Phospho-S6 (S235/236) flow cytometry for single-cell analysis

  • Particularly useful for analyzing heterogeneous populations

  Subcellular localization:

  • Immunofluorescence to track mTORC1 recruitment to lysosomes

  • Co-localization of mTOR with lysosomal markers (LAMP1/2)

  • Recruitment of RagC to lysosomes

• Advanced methodological approaches:

  Proximity ligation assays:

  • To detect RagC-Raptor interactions in situ

  • Visualize RagC-RagA/B heterodimer formation

  FRET/BRET biosensors:

  • For real-time monitoring of mTORC1 activity

  • Tracking RRAGC-nucleotide binding states

  Transcriptional profiling:

  • RNA-seq to identify gene expression changes

  • Focus on mTORC1-responsive genes (translation factors, metabolic enzymes)

  Functional readouts:

  • Protein synthesis rates (puromycin incorporation)

  • Cell size measurements

  • Autophagy markers (LC3B-II, p62)

• Critical controls for data interpretation:

  • Compare responses in amino acid-independent pathways (e.g., insulin stimulation)

  • Include RagC phosphorylation mutants (S2A/S21A/T394A)

  • Test rapamycin sensitivity to confirm mTORC1 dependency

  • Include heterozygous RagC mutant cells to model FL mutations accurately

These methodological approaches provide a comprehensive framework for studying how RRAGC mediates amino acid sensing and mTORC1 activation in normal physiology and disease states like follicular lymphoma .

What are emerging areas of research regarding RRAGC function beyond mTORC1 regulation?

Several cutting-edge research directions are expanding our understanding of RRAGC beyond its canonical role in mTORC1 regulation:

• Non-canonical mTORC1 complex formation:

  • RRAGC plays a central role in the non-canonical mTORC1 complex that functions independently of RHEB

  • This complex specifically mediates phosphorylation of MiT/TFE transcription factors TFEB and TFE3

  • GDP-bound RRAGC mediates recruitment of these factors, revealing a new regulatory mechanism

• Role in B cell-specific functions and adaptive immunity:

  • RRAGC mutations enhance B cell activation and proliferation in response to immune stimuli

  • RagC mutant mice show exaggerated germinal center (GC) formation after immunization

  • B cells from these mice exhibit enhanced antibody production and class switching

  • Suggests RRAGC has specialized functions in immune response regulation

• Developmental biology contributions:

  • De novo missense variants in RRAGC have been linked to a fatal mTORopathy of early childhood

  • Suggests essential roles in developmental processes

  • Research opportunities in understanding tissue-specific requirements for RRAGC during development

• Metabolic integration beyond amino acids:

  • Emerging evidence that RRAGC may respond to other metabolic signals beyond amino acids

  • Studies on inosine-enhanced tumor mitochondrial respiration show involvement of Rag GTPases

  • Potential connection to nascent protein synthesis under nutrient starvation conditions

• Therapeutic targeting approaches:

  • Designing specific inhibitors of mutant RRAGC proteins for cancer therapy

  • Exploring the potential of modulating RRAGC phosphorylation as a therapeutic strategy

  • Developing biomarkers for patient stratification for mTOR inhibitor therapy

• Advanced technological applications:

  • CRISPR base editing to create precise RRAGC mutations

  • Cryo-EM studies of RRAGC-containing complexes to understand structural dynamics

  • Single-cell analyses to capture heterogeneity in RRAGC-dependent signaling

  • Optogenetic approaches to control RRAGC activity with spatiotemporal precision

These emerging research areas highlight the expanding significance of RRAGC beyond its established role in amino acid sensing and mTORC1 regulation, with important implications for immunology, development, metabolism, and therapeutic development .

How can phospho-specific RRAGC antibodies advance our understanding of its regulation?

Development and application of phospho-specific RRAGC antibodies would significantly advance our understanding of RRAGC regulation and function:

• Key phosphorylation sites to target:

  • S2 and S21: Growth factor-responsive N-terminal sites

  • T394: C-terminal phosphorylation site

  • All three sites play roles in autoregulatory mechanisms of mTORC1 activity

• Methodological applications:

  Signaling dynamics analysis:

  • Temporal profiling of RRAGC phosphorylation in response to growth factors

  • Correlation with mTORC1 activity states

  • Single-cell analysis of phosphorylation heterogeneity

  Spatial regulation studies:

  • Immunofluorescence to track phosphorylated RRAGC localization

  • Determine if phosphorylation affects lysosomal recruitment

  • Co-localization with mTORC1 components

  Pathway cross-talk mapping:

  • Identify how growth factor and amino acid sensing pathways intersect

  • Study how RRAGC phosphorylation responds to various stimuli

  • Examine feedback regulation mechanisms

• Technical considerations for phospho-antibody development:

  Immunogen design:

  • Use phosphopeptides corresponding to sequences surrounding S2, S21, and T394

  • Include carrier proteins for enhanced immunogenicity

  • Consider multiple host species for diverse antibody repertoires

  Validation approaches:

  • Test against phospho-null mutants (S2A, S21A, T394A)

  • Validate with phosphatase treatment controls

  • Confirm using kinase assays with recombinant proteins

• Research applications:

  Normal physiology:

  • Tissue-specific phosphorylation patterns

  • Developmental regulation of RRAGC phosphorylation

  • Response to physiological stresses (fasting, exercise)

  Disease contexts:

  • Altered phosphorylation patterns in follicular lymphoma

  • Changes in metabolic disorders

  • Phosphorylation status in response to therapies

The development of phospho-specific RRAGC antibodies would enable researchers to directly monitor the activation state of RRAGC and study its regulatory mechanisms in various physiological and pathological contexts. This would significantly advance our understanding of how RRAGC contributes to nutrient sensing and mTORC1 regulation .

How do we reconcile conflicting findings about RRAGC function in different experimental models?

Interpreting seemingly conflicting results about RRAGC function requires careful methodological consideration of experimental models:

• Cell type-specific effects:

  • B lymphocytes show distinct RRAGC mutation effects compared to other cell types

  • RagC mutations in follicular lymphoma have different consequences than in other cancer types

• In vitro vs. in vivo discrepancies:

  • RagC mutant phenotypes can differ between cultured cells and animal models

  • Cell culture fails to capture tissue microenvironment effects

• Heterozygous vs. homozygous mutation effects:

  • RRAGC mutations in follicular lymphoma are heterozygous

  • Some studies use homozygous models that may exaggerate phenotypes

  • Results show that RagC activating mutations when expressed endogenously and in heterozygosity have modest but significant effects

  • Proper comparison requires matched gene dosage across studies

• Differential effects of specific mutations:

  • Not all RRAGC mutations have identical effects:

    • Some primarily affect nucleotide binding

    • Others alter protein-protein interactions

    • Some impact both functions

  • Detailed biochemical characterization of each mutation is essential for interpretation

• Interaction with genetic background:

  • RRAGC mutation effects may depend on co-occurring mutations

  • In follicular lymphoma, RRAGC mutations often co-occur with ATP6V1B2 and ATP6AP1 mutations (v-ATPase components)

  • Mouse models may lack relevant genetic context

  • Solution: Generate compound mutant models reflecting human disease genetics

• Experimental conditions affecting outcomes:

  • Amino acid availability dramatically affects results

  • Growth factor concentrations in media influence RRAGC phosphorylation

By systematically addressing these variables, researchers can better interpret seemingly conflicting findings about RRAGC function across different experimental systems and build a more cohesive understanding of its biological roles .

What are the current limitations in RRAGC antibody technology and how might they be addressed?

Current RRAGC antibody technologies face several limitations that impact research quality and reproducibility:

• Specificity challenges:

  • Limited validation against knockout controls

  • Potential cross-reactivity with other Rag family proteins (RagA, RagB, RagD)

  • Current solution: Validate antibodies using CRISPR/Cas9 knockout cells

  Future improvements:

  • Development of monoclonal antibodies against unique epitopes

  • Comprehensive validation against all Rag family members

  • Creation of standardized validation protocols

• Conformational state detection:

  • Current antibodies cannot distinguish GTP-bound vs. GDP-bound RRAGC

  • Unable to directly measure activation state

  Methodological advances needed:

  • Development of conformation-specific antibodies

  • Creation of biosensors that report nucleotide binding state

  • Fluorescent probes for live-cell imaging of RRAGC activation

• Phosphorylation site specificity:

  • Lack of commercial antibodies for specific phosphorylation sites (S2, S21, T394)

  • Inability to track multiple phosphorylation events simultaneously

  Future directions:

  • Development of site-specific phospho-antibodies

  • Multiplexed detection systems for multiple phosphorylation sites

  • Nanobody-based detection systems for improved specificity

• Subcellular localization studies:

  • Current antibodies often perform poorly in immunofluorescence

  • Challenges in detecting endogenous RRAGC at lysosomes

  Possible solutions:

  • Optimized fixation protocols for preserving epitope accessibility

  • Super-resolution compatible antibodies

  • Proximity labeling approaches (BioID, APEX) for interaction studies

• Quantification limitations:

  • Semi-quantitative nature of Western blotting

  • Challenges in absolute quantification of RRAGC levels

  Advanced approaches:

  • Development of quantitative ELISA systems

  • Mass spectrometry-based absolute quantification

  • Single-molecule detection methods

• Technical specifications for improved antibodies:

  Desired Characteristic	Current Status	Future Goal
  Epitope mapping	Limited	Precise epitope definition
  Validation breadth	Few applications	Comprehensive validation
  Species reactivity	Mostly human/mouse	Expanded cross-species reactivity
  Sensitivity	Variable	Consistent detection of endogenous levels
  Format options	Limited	Multiple formats (unlabeled, fluorescent, HRP)

• Industry-academic collaboration opportunities:

  • Cooperative validation initiatives

  • Open-source antibody characterization databases

  • Pre-competitive consortia for next-generation reagent development